Abstract

Differentiated somatic cells can be reprogrammed into totipotent embryos through somatic cell nuclear transfer. However, most cloned embryos arrest at early stages and the underlying molecular mechanism remains largely unexplored. Here, we first developed a somatic cell nuclear transfer embryo biopsy system at two- or four-cell stage, which allows us to trace the developmental fate of the biopsied embryos precisely. Then, through single-cell transcriptome sequencing of somatic cell nuclear transfer embryos with different developmental fates, we identified that inactivation of Kdm4b, a histone H3 lysine 9 trimethylation demethylase, functions as a barrier for two-cell arrest of cloned embryos. Moreover, we discovered that inactivation of another histone demethylase Kdm5b accounts for the arrest of cloned embryos at the four-cell stage through single-cell analysis. Co-injection of Kdm4b and Kdm5b can restore transcriptional profiles of somatic cell nuclear transfer embryos and greatly improve the blastocyst development (over 95%) as well as the production of cloned mice. Our study therefore provides an effective approach to identify key factors responsible for the developmental arrest of somatic cell cloned embryos.

Highlights

  • Differentiated somatic cells can be reprogrammed into totipotent embryos through somatic cell nuclear transfer (SCNT)

  • Establishment of an embryo biopsy system to trace the developmental fate of SCNT embryos Compared with normally fertilized embryos, a large proportion of SCNT embryos arrested at early developmental stages

  • We first confirmed that the removal of one blastomere at the two- or four-cell stage did not influence the developmental capacity of the biopsied SCNT embryos (Figure 1c)

Read more

Summary

Introduction

Differentiated somatic cells can be reprogrammed into totipotent embryos through somatic cell nuclear transfer (SCNT). The successful reprogramming of human somatic cells by SCNT and the derivation of nuclear transfer embryonic stem cells (ntESCs) has been demonstrated to be feasible [4]. The derivation of human ntESCs from aged adult and patient donor cells [5, 6] holds promise for future clinical applications of therapeutic cloning. These studies indicate that the future development prospect of SCNT is captivating. SCNT embryos are usually incapable of repressing some somatic genes inherited from donor cells [3, 9, 10]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call